These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 389502)

  • 21. Prostacyclin: its biosynthesis, actions, and clinical potential.
    Dusting GJ; Moncada S; Vane JR
    Adv Prostaglandin Thromboxane Leukot Res; 1982; 10():59-106. PubMed ID: 6216790
    [No Abstract]   [Full Text] [Related]  

  • 22. [Change of blood platelet activity in patients with chronic uremia].
    Cordonnier D; Kolodie L; Hollard D; Muller JM
    J Urol Nephrol (Paris); 1969; 75(4):289-301. PubMed ID: 5370827
    [No Abstract]   [Full Text] [Related]  

  • 23. The decreased circulating platelet mass and its relation to bleeding time in chronic renal failure.
    Michalak E; Walkowiak B; Paradowski M; Cierniewski CS
    Thromb Haemost; 1991 Jan; 65(1):11-4. PubMed ID: 2024233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased prostacyclin production from human veins by dipyridamole: an in vitro and ex vivo study.
    Costantini V; Talpacci A; Bastiano ML; Boschetti E; Cipolloni S; Bisacci R; Nenci GG
    Biomed Biochim Acta; 1990; 49(4):263-71. PubMed ID: 2119575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet hyperactivity in acute myocardial infarction in man--effects of prostacyclin.
    Mueller HS; Rao PS; Greenberg MA; Buttrick PM; Sussman II; Levite HA; Grose RM; Perez-Davila V; Strain JE; Spaet TH
    Herz; 1986 Apr; 11(2):116-26. PubMed ID: 2939012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prostacyclin synthesis-stimulating plasma factor in different age groups].
    Leithner C; Kefalides A; Hoche C; Sinzinger H
    Aktuelle Gerontol; 1982 Nov; 12(6):217-9. PubMed ID: 6130715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostacyclin in physiology and pathophysiology.
    Vane JR; Bunting S; Moncada S
    Int Rev Exp Pathol; 1982; 23():161-207. PubMed ID: 6806207
    [No Abstract]   [Full Text] [Related]  

  • 28. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus.
    Patrono C; Ciabattoni G; Remuzzi G; Gotti E; Bombardieri S; Di Munno O; Tartarelli G; Cinotti GA; Simonetti BM; Pierucci A
    J Clin Invest; 1985 Sep; 76(3):1011-8. PubMed ID: 3900132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of uremia on platelet contractile force, clot elastic modulus and bleeding time in hemodialysis patients.
    Brophy DF; Martin EJ; Carr SL; Kirschbaum B; Carr ME
    Thromb Res; 2007; 119(6):723-9. PubMed ID: 16793120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostacyclin production by whole blood from children: impairment in the hemolytic uremic syndrome and excessive formation in chronic renal failure.
    Deckmyn H; Proesmans W; Vermylen J
    Thromb Res; 1983 Apr; 30(1):13-8. PubMed ID: 6344317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eicosanoids of platelets and vascular wall in chronic renal insufficiency.
    Sinzinger H; Leithner C
    Am J Nephrol; 1987; 7(3):212-20. PubMed ID: 3115103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Juvenile diabetes mellitus: decreased prostacyclin (PGI2) synthesis in the vascular wall].
    Silberbauer K; Schernthaner G; Sinzinger H; Winter M; Piza-Katzer H
    Vasa; 1979; 8(3):213-6. PubMed ID: 390914
    [No Abstract]   [Full Text] [Related]  

  • 34. Enhanced prostacyclin formation in veins of women under chronical treatment with oral contraceptive drugs.
    Sinzinger H; Klein K; Kaliman J; Silberbauer K; Feigl W
    Pharmacol Res Commun; 1980 Jun; 12(6):515-21. PubMed ID: 6995996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PGI2 production by rat blood vessels: diminished prostacyclin formation in veins compared to arteries.
    Skidgel RA; Printz MP
    Prostaglandins; 1978 Jul; 16(1):1-16. PubMed ID: 360298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.
    Moncada S; Higgs EA; Vane JR
    Lancet; 1977 Jan; 1(8001):18-20. PubMed ID: 63657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uremia as a cause of bleeding.
    Andrassy K; Ritz E
    Am J Nephrol; 1985; 5(5):313-9. PubMed ID: 3904449
    [No Abstract]   [Full Text] [Related]  

  • 38. Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times.
    Remuzzi G; Marchesi D; Livio M; Cavenaghi AE; Mecca G; Donati MB; de Gaetano G
    Thromb Res; 1978 Dec; 13(6):1007-15. PubMed ID: 373157
    [No Abstract]   [Full Text] [Related]  

  • 39. Platelet-endothelial prostaglandin biochemical imbalance in sudden infant death syndrome in the newborn: capillary endothelial cell deficiency and/or lag in maturation of prostacyclin synthetase.
    Hokama Y
    Med Hypotheses; 1978; 4(4):303-5. PubMed ID: 362136
    [No Abstract]   [Full Text] [Related]  

  • 40. Prostacyclin (PGI2) and bleeding time in uremic patients.
    Remuzzi G; Cavenaghi AE; Mecca G; Donati MB; de Gaetano G
    Thromb Res; 1977 Dec; 11(6):919-20. PubMed ID: 341416
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.